Marksans Pharma Limited (MARKSANS) AI Stock Analysis

Top Page

Marksans Pharma Limited

(NSE:MARKSANS)

Select Model

Rating:70Outperform

Price Target:INR 326.00▲(6.31% Upside)

Action:upgraded

Date:08/17/26

The score is driven primarily by strong financial quality (steady growth, solid profitability, and low leverage), partially offset by margin compression and historically uneven cash conversion. Technically, the uptrend is strong but appears overextended, and valuation is relatively expensive with a low dividend yield.

Positive Factors

Steady Revenue GrowthSustained revenue expansion indicates continuing demand for Marksans Pharma’s generic products across its markets. Although FY2026 growth moderated, the multi-year pattern supports an established commercial platform and provides a durable base for future earnings growth.

Negative Factors

Gross Margin CompressionThe sharp FY2026 gross-margin decline signals pressure on the economics of products sold, whether from mix or costs as indicated in the financial analysis. If persistent, this could reduce operating leverage and limit how much revenue growth translates into profit.

Marksans Pharma Limited (MARKSANS) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 152.69B
Dividend Yield: 0.29%
Average Volume (3M): 215.98K
Price to Earnings (P/E): 26.8
Beta (1Y): 1.22
Revenue Growth: 19.59%
EPS Growth: 47.58%
Country: India
Employees: 1,685
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - General

Marksans Pharma Limited Business Overview & Revenue Model

Company Description

Marksans Pharma Limited, along with its subsidiaries, operates internationally, engaging in the full spectrum of generic pharmaceutical formulation activities, from research and development and manufacturing to marketing, distribution, and sales. The...

Marksans Pharma Limited Financial Statement Overview

Summary

Fundamentals are solid overall: steady multi-year revenue growth and durable mid-teens net margins, supported by a conservatively financed balance sheet with low leverage. Offsetting factors are FY2026 gross margin compression and historically uneven cash conversion (despite a strong FY2026 cash-flow rebound), which reduces confidence in consistency.

Income Statement

78Positive

Balance Sheet

86Very Positive

Cash Flow

70Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	31.72B	29.51B	26.23B	21.77B	18.52B	14.80B
Gross Profit	14.06B	11.57B	14.79B	11.03B	9.31B	7.32B
EBITDA	7.55B	6.03B	5.29B	5.09B	3.99B	3.01B
Net Income	5.17B	4.18B	3.81B	3.14B	2.66B	1.85B
Balance Sheet
Total Assets	0	38.61B	32.40B	26.81B	21.90B	16.40B
Cash, Cash Equivalents and Short-Term Investments	9.91B	9.90B	7.05B	7.00B	7.19B	3.47B
Total Debt	0	3.43B	3.22B	2.44B	1.23B	1.11B
Total Liabilities	-30.53B	8.08B	7.50B	5.95B	4.25B	4.17B
Stockholders Equity	30.53B	30.23B	24.67B	20.65B	17.45B	12.02B
Cash Flow
Free Cash Flow	19.97M	3.51B	337.45M	215.69M	1.84B	529.27M
Operating Cash Flow	751.86M	4.82B	2.07B	2.30B	2.37B	992.57M
Investing Cash Flow	-364.77M	-2.75B	-490.09M	-1.41B	-2.59B	-416.86M
Financing Cash Flow	-528.77M	-681.43M	-651.46M	-687.27M	1.98B	795.11M

Marksans Pharma Limited Technical Analysis

Technical Analysis SentimentPositive

Last Price306.65

Price Trends

50DMA320.92Negative

100DMA294.11Positive

200DMA239.45Positive

Market Momentum

MACD-4.84Negative

RSI47.47Neutral

STOCH74.81Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MARKSANS, the sentiment is Positive. The current price of 306.65 is below the 20-day moving average (MA) of 309.74, below the 50-day MA of 320.92, and above the 200-day MA of 239.45, indicating a neutral trend. The MACD of -4.84 indicates Negative momentum. The RSI at 47.47 is Neutral, neither overbought nor oversold. The STOCH value of 74.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MARKSANS.

Marksans Pharma Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:MARKSANS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:CIPLA	79Outperform	INR 1.11T	38.44	―	2.10%	-0.74%	-46.77%
IN:MARKSANS	70Outperform	INR 138.96B	26.84	―	0.29%	19.59%	47.58%
IN:SANOFI	70Outperform	INR 73.80B	20.24	―	3.84%	-5.74%	2.30%
IN:GLAXO	68Neutral	INR 420.73B	39.56	―	2.29%	5.75%	12.41%
IN:PFIZER	67Neutral	INR 168.67B	22.95	―	2.03%	10.69%	-9.09%
IN:GLAND	65Neutral	INR 511.12B	45.19	―	0.65%	17.57%	46.53%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

IN:MARKSANS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:MARKSANS	Marksans Pharma Limited	306.65	116.72	61.46%
IN:CIPLA	Cipla Ltd	1380.00	-117.54	-7.85%
IN:GLAND	Gland Pharma Ltd.	3097.50	1140.16	58.25%
IN:GLAXO	GlaxoSmithKline Pharmaceuticals Limited	2483.55	-135.33	-5.17%
IN:PFIZER	PFIZER LIMITED	3687.05	-1407.11	-27.62%
IN:SANOFI	Sanofi India Limited	3204.40	-1441.42	-31.03%

Marksans Pharma Limited Corporate Events

Marksans Pharma Opens SEBI-Mandated Window for Re-Lodging Physical Share Transfers

Sep 17, 2026

Marksans Pharma Limited has announced the opening of a special window for shareholders to re-lodge transfer requests for physical shares purchased before April 1, 2019 that were previously rejected or not processed due to documentation deficiencies....

Marksans Pharma to Join Elara India Dialogue 2026 Investor Meet

Sep 1, 2026

Marksans Pharma Limited has scheduled participation in the Ashwamedh – Elara India Dialogue 2026, an investor and analyst meeting to be held on 2 September 2026 at the Hyatt in Santacruz East, Mumbai. The company emphasized that no unpublished...

Marksans Pharma Files Business Responsibility and Sustainability Report for FY 2025-26

Aug 4, 2026

Marksans Pharma Limited, a Mumbai-based listed pharmaceutical manufacturer, derives all its revenue from research, production and sale of generic, specialty, OTC and prescription formulations. Its portfolio includes tablets, capsules, soft gels, oint...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 17, 2026

Marksans Pharma Limited AI Stock Analysis

Top Page